Financial Data and Key Metrics Changes - The Oncology Institute achieved a revenue increase of approximately 28% year-over-year, surpassing $500 million for the first time in its history, with total revenue for Q4 2025 reaching $142 million, a 41.6% year-over-year growth [5][20] - Adjusted EBITDA for Q4 2025 was $147,000, improving from a loss of $7.8 million in Q4 2024, marking the first profitable quarter from an adjusted EBITDA perspective as a public company [4][24] - SG&A expenses decreased by 2% year-over-year, reflecting operational efficiency, with SG&A as a percentage of revenue dropping from 24.8% to 19.7% [7][23] Business Line Data and Key Metrics Changes - The fee-for-service business grew 9% year-over-year from $136.2 million to $148.5 million, while the capitation business grew 17.2% year-over-year from $68.7 million to $80.5 million [17] - Pharmacy revenue grew 49.6% year-over-year from $179.9 million to $269.2 million, driven by improved prescription attachment rates [18] Market Data and Key Metrics Changes - The company expanded its capitated care model, initiating 9 new capitated contracts in California, Florida, and Nevada, adding approximately 260,000 patient lives under management [5][8] - The Florida Oncology Network platform grew to approximately 207 participating providers, supporting a hybrid model of patient care [10] Company Strategy and Development Direction - The Oncology Institute aims to continue scaling its value-based care platform, with a focus on expanding payer partnerships and achieving sustainable profitability [11][13] - The company plans to launch a proprietary network portal in Q2 2026 to enhance provider engagement and improve operational efficiencies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year positive adjusted EBITDA in 2026, driven by strong growth in the delegated capitation model [4][11] - The impact of the Inflation Reduction Act on the company's revenue is expected to be minor, with management indicating multiple strategies to offset any potential negative effects [15][16] Other Important Information - The company reduced debt on its convertible preferred note by $24 million, ending the year with $33.6 million in cash [8] - The leadership team was strengthened with new appointments, enhancing the company's ability to scale and execute its growth strategy [10][12] Q&A Session Summary Question: What drove the higher dispensing revenue in the quarter? - Management attributed the strong performance to operational execution in mitigating prescription leakage and strong patient encounter growth related to capitated contracts [30][31] Question: Will the Elevance contract size double in Florida in 2026? - Yes, that is the goal [32] Question: What is the size of the total addressable market for Elevance or Humana? - There is significant opportunity for growth, with many multiples of current capitated revenue available in Florida [34][35] Question: How are margins looking for capitated revenue? - Performance in terms of volume and medical loss ratio (MLR) is as expected, with no surprises [36] Question: Will SG&A improve in 2026? - Improvements are expected, but not to the same degree as in 2025 due to growth investments [65]

The Oncology Institute (NasdaqCM:TOI) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsDaniel Virnich - CEOMark Hueppelsheuser - General CounselRob Carter - CFOYuan Zhi - Managing Director of Healthcare Equity ResearchConference Call ParticipantsDavid Larsen - Managing Director and Healthcare IT and Digital Health AnalystMatthew Shea - Equity Research AnalystOperatorGreetings, and welcome to The Oncology Institute Fourth Quarter 2025 Earnings Call. At this time, all participants are in a ...